Topic: GlaxoSmithKline plc

Landmark lupus drug Benlysta approved in Europe

Reuters US Online Report Health News - 204 days ago
LONDON (Reuters) - Benlysta, the first new treatment for lupus in half a century, was approved for use in Europe, the drug's discoverer Human Genome Sciences and partner GlaxoSmithKline said on Thursday.The drug, which combats lupus -- a disease that causes the ...
Read More...

Human Genome Sciences and GlaxoSmithKline Announce Topline 76-Week Results of Phase 3 Trial of Benlysta in Systemic Lupus Erythematosus

Drugs.com - 656 days ago
HGSI) and GlaxoSmithKline PLC (GSK) today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTAT (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). At Week 76 in the BLISS-76 study, belimumab plus standard of ...

Batch of swine flu vaccines studied in Canada

AP News - 802 days ago
GlaxoSmithKline studies batch of swine flu vaccines in Canada over allergy fearsCanadian doctors have been advised not to use a batch of 170,000 doses of swine flu vaccine while authorities investigate reports of allergic reactions among recipients, drug maker GlaxoSmithKline PLC said ...
Read More...

Human Genome reports positive data on lupus drug

AP Features - 822 days ago
Human Genome Sciences and GlaxoSmithKline said Monday their experimental lupus treatment passed another key goal on its path to potentially becoming the first new drug for the disease in decades.Shares of Human Genome Sciences soared more than 35 percent on the report.Wall ...
Read More...

Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of Benlysta in Systemic Lupus Erythematosus

Drugs.com - 824 days ago
BENLYSTA (belimumab) 10 mg/kg plus standard of care met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo plus standard of care at Week 52 in BLISS-76 -. HGSI) and GlaxoSmithKline PLC (GSK) today announced ...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for Benlysta in Systemic Lupus Erythematosus

Drugs.com - 926 days ago
BENLYSTA (belimumab) met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo in BLISS-52 - - First drug for lupus to reach this advanced stage of clinical development and achieve positive results, in the largest ...

Glaxo and Dynavax sign development deal

AP News - 1144 days ago
GlaxoSmithKline and Dynavax announce deal to develop autoimmune and inflammatory disease drugsBritish drug maker GlaxoSmithKline PLC said Wednesday it will pay U.S. biotechnology company Dynavax Technologies Corp. $10 million upfront in a research deal to develop drugs to treat autoimmune and inflammatory ...
Read More...